Brown eyes are more likely to develop iris melanoma

Article

Patients with brown irises are most likely to develop melanomas.

Patients with brown irises are most likely to develop melanomas, according to recent study results published in the Archives of Ophthalmology.

The investigation, led by Dr Samira Khan, New York University School of Medicine, New York, USA, conducted a retrospective chart review on 131 iris melanoma patients from eight eye cancer centres across six countries.

Internet-assisted multicentre, privacy-protected on-line data entry was possible due to the creation of a computer program. Patient and tumour characteristics, ocular and angle abnormalities, management, histopathology and outcomes were among the factors included in the statistical analysis.

Of the patients studied, 65.6% had brown irises, 62.2% had blue-grey, 29.1% had green-hazel, 9.9% had amelanotic and 6.9% had multicoloured irises.

Patients experienced a variety of disorders including iritis, glaucoma, hyphaema and sector cataract. The results of high-frequency ultrasonograpy presented a largest mean tumour diameter of 4.9 mm, a mean maximum tumor thickness of 1.9 mm, angle blunting in 52% of patients, iris root disinsertion in 9% and posterior iris pigment epithelium displacement in 9%.

The American Joint Commission on Cancer-Internaional Union Against Cancer Classification was used to identify T1 tumours in 56% of patients, T2 tumours in 34%, T3 tumours in 2% and T4 tumours in 1%.

At five years the Kaplan-Meier analysis demonstrated a 10.7% risk of metastatic melanoma. The histopathologic grades were G1-spindle in 54% of patients, G2-mixed in 28%, G3-epithelioid in 5%, and undetermined in 13% of cell types.

The iris melanomas were commonly found in the inferior quadrants of patients with light irides. Angle blunting and spindle cell histopathology are linked to small and unifocal melanomas.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.